Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002474 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer
A Phase 2 study, sponsored by Loyola University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002474: Completed Phase 2 study, sponsored by Loyola University.
NCT00002474 is a Phase 2 study that has completed, run by Loyola University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002474, a Phase 2 study, has completed, sponsored by Loyola University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: This phase II trial is studying how well chemotherapy and autologous bone marrow transplant work in treating patients with refractory or recurrent ovarian cancer.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- PROCEDURE bone marrow ablation with stem cell support
- PROCEDURE autologous bone marrow transplantation
- DRUG mitoxantrone hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 1991-02 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00002474 record still lists
NCT00002474 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00002474 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002474 about?
NCT00002474 is a clinical study titled "Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer". RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, carboplatin, and mitoxantrone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with autologous bone marrow transplant may allow the doctor to ...
What is the current status of trial NCT00002474?
This trial is currently completed. It is a Phase 2 study. The study started on 1991-02. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00002474?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), bone marrow ablation with stem cell support (PROCEDURE), autologous bone marrow transplantation (PROCEDURE), mitoxantrone hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002474?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia